Pathology: es-BC - TNBC - NA - all population; es-BC - TNBC - NA - PDL1 positive;
es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | |||||
NeoTRIPaPDLA, 0 | IMpassion-031 (all population), 2020 | GeparNuevo, 2019 | KEYNOTE-522, 2020 | IMpassion-031 (PDL1>1%), 2020 | ||
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | 2 | T1 | T1 | |||
atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | ||||
pembrolizumab alone | 1 | T1 | ||||
durvalumab alone | 1 | T1 | ||||
carboplatin plus nab-paclitaxel | 0 | T0 | ||||
placebo plus SoC | 0 | T0 | T0 | |||
placebo | 0 | T0 | T0 |